AQR Capital Management’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-92,469
| Closed | -$11.9M | – | 3476 |
|
|
2025
Q2 | $11.9M | Sell |
92,469
-55,802
| -38% | -$5.8M | 0.01% | 915 |
|
|
2025
Q1 | $13.1M | Buy |
148,271
+3,578
| +2% | +$349K | 0.01% | 803 |
|
|
2024
Q4 | $12.6M | Buy |
144,693
+30,635
| +27% | +$2.81M | 0.02% | 763 |
|
|
2024
Q3 | $10.6M | Buy |
114,058
+35,955
| +46% | +$3.57M | 0.01% | 785 |
|
|
2024
Q2 | $8.42M | Buy |
78,103
+18,099
| +30% | +$1.81M | 0.01% | 816 |
|
|
2024
Q1 | $5.69M | Buy |
60,004
+20,805
| +53% | +$1.78M | 0.01% | 923 |
|
|
2023
Q4 | $3.62M | Buy |
39,199
+13,820
| +54% | +$895K | 0.01% | 1089 |
|
|
2023
Q3 | $1.27M | Buy |
+25,379
| New | +$1.36M | ﹤0.01% | 1514 |
|
|
2023
Q1 | – | Sell |
-9,628
| Closed | -$422K | – | 2169 |
|
|
2022
Q4 | $422K | Buy |
+9,628
| New | +$462K | ﹤0.01% | 1869 |
|
|
2022
Q2 | – | Sell |
-22,827
| Closed | -$1.46M | – | 2191 |
|
|
2022
Q1 | $1.46M | Buy |
22,827
+2,725
| +14% | +$196K | ﹤0.01% | 1350 |
|
|
2021
Q4 | $2.15M | Sell |
20,102
-10,232
| -34% | -$1.07M | ﹤0.01% | 1123 |
|
|
2021
Q3 | $3.12M | Sell |
30,334
-835
| -3% | -$77.8K | 0.01% | 949 |
|
|
2021
Q2 | $2.74M | Sell |
31,169
-5,279
| -14% | -$484K | ﹤0.01% | 1059 |
|
|
2021
Q1 | $3.54M | Buy |
36,448
+8,097
| +29% | +$808K | 0.01% | 921 |
|
|
2020
Q4 | $3.18M | Buy |
28,351
+9,136
| +48% | +$963K | 0.01% | 945 |
|
|
2020
Q3 | $1.78M | Sell |
19,215
-7,578
| -28% | -$584K | ﹤0.01% | 1162 |
|
|
2020
Q2 | $2.09M | Buy |
26,793
+1,143
| +4% | +$77.3K | ﹤0.01% | 1141 |
|
|
2020
Q1 | $1.5M | Buy |
25,650
+13,483
| +111% | +$868K | ﹤0.01% | 1182 |
|
|
2019
Q4 | $975K | Buy |
12,167
+3,112
| +34% | +$233K | ﹤0.01% | 1522 |
|
|
2019
Q3 | $665K | Sell |
9,055
-293
| -3% | -$25.3K | ﹤0.01% | 1658 |
|
|
2019
Q2 | $882K | Buy |
+9,348
| New | +$772K | ﹤0.01% | 1541 |
|
|
2018
Q4 | – | Sell |
-16,558
| Closed | -$1.29M | – | 2192 |
|
|
2018
Q3 | $1.29M | Sell |
16,558
-7,384
| -31% | -$513K | ﹤0.01% | 1592 |
|
|
2018
Q2 | $1.52M | Sell |
23,942
-3,312
| -12% | -$264K | ﹤0.01% | 1550 |
|
|
2018
Q1 | $2.5M | Sell |
27,254
-6,815
| -20% | -$587K | ﹤0.01% | 1254 |
|
|
2017
Q4 | $2.57M | Sell |
34,069
-16,927
| -33% | -$1.19M | ﹤0.01% | 1273 |
|
|
2017
Q3 | $3.55M | Sell |
50,996
-4,599
| -8% | -$246K | ﹤0.01% | 1165 |
|
|
2017
Q2 | $2.82M | Buy |
55,595
+31,534
| +131% | +$1.34M | ﹤0.01% | 1252 |
|
|
2017
Q1 | $962K | Buy |
24,061
+13,770
| +134% | +$493K | ﹤0.01% | 1693 |
|
|
2016
Q4 | $289K | Buy |
+10,291
| New | +$310K | ﹤0.01% | 2065 |
|
Other funds holding BPMC
IA
HNB
AQR Capital Management's BPMC Position: Q3 2025 in Review
AQR Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 92,469 shares — an estimated $11.9M sold.
AQR Capital Management first reported a position in BPMC in Q4 2016 and held it in 29 quarters. The position peaked at $13.1M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- AQR Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- AQR Capital Management sold 92,469 Blueprint Medicines shares in Q3 2025, an estimated $11.9M.
- AQR Capital Management first reported a position in Blueprint Medicines in Q4 2016 and held it in 29 quarters.
- AQR Capital Management's Blueprint Medicines position peaked at $13.1M in Q1 2025.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.